Sun Healthcare Solution

Sun Healthcare Solution is Sun Life Indonesia’s flagship conventional hospitalization product — an 8-tier, Yearly Renewable Term medical policy that pays inpatient and outpatient bills on a Sesuai Tagihan basis within a per-tier annual ceiling. Three structural features carry the agent narrative. First, the Booster — every Plus-tier (Opal Plus, Topaz Plus, Emerald Plus, Safir Plus) auto-increments the annual ceiling each policy year until it reaches a hard cap (Rp 1B for Opal Plus up to Rp 20B for Safir Plus); this offsets medical inflation without the customer doing anything. Second, a built-in death benefit on the Plus tiers ranging from Rp 50M (Opal Plus) to Rp 200M (Safir Plus), paid if the Tertanggung dies before age 65 — distinctive in the hospitalization category, where peers mostly bundle no life cover at all. Third, Simplified Issuance Offer (SIO) — no medical check at issuance, just a health questionnaire. The product trades that ease for non-disclosure-at-claim-time risk. In one line: An 8-tier conventional hospitalization rider with an annual-ceiling Booster on every Plus tier, a built-in death benefit up to Rp 200M, and a no-medical-check onboarding — sold as Sun Life’s affluent-tier medical answer with Worldwide cover available on the top tier (but no USA, by default).

---

The brochure publishes a Topaz Plus illustrative case: 40-year-old male, annual premium Rp 5,931,000, Initial Annual Ceiling Rp 3 billion, Booster Rp 150 million per year up to Rp 6 billion maximum, Death Benefit Rp 100 million. The Tertanggung is hospitalized for dengue in Year 1, then for typhoid at age 48 in Year 9.

Critical insight for the agent narrative: the brochure decoration uses a Topaz Plus mid-tier example with a clean dengue claim. The structural value of the Plus tiers emerges later — at year 10, 15, 20 of holding, when the Booster has stepped the ceiling well above the starting figure and the customer has not had to upgrade plans to keep up with medical inflation. For genuinely catastrophic claims (multi-billion-rupiah cancer protocols or transplant pathways), Safir Plus at Rp 10B initial / Rp 20B maximum is the only tier that meaningfully reaches the highest-cost private cancer protocols at Singapore prices.

---

Sweet Spot — Lead with Sun Healthcare Solution

• Indonesian middle and upper-affluent customers wanting a standalone hospitalization product (not a rider) with cashless cover at Sun Life network hospitals
• Households age 30–55 with mid-to-upper income, fit for Topaz Plus or Emerald Plus at Rp 3B–4.5B initial ceiling stepping up via Booster
• Cross-border families with Singapore and Malaysia treatment patterns — Topaz Plus and up cover Indonesia + Malaysia + Singapore at full Plus-tier rate
• Customers who explicitly value medical-inflation protection via the auto-Booster mechanism without having to renegotiate plan tiers later
• Customers who want a small death-benefit kicker (Rp 50M–Rp 200M) bundled inside a medical policy — useful as a basic funeral / immediate-cash layer, not as legacy planning
• Customers comfortable with no-medical-check onboarding via the SIO — fast issuance, simple health questionnaire
• Affluent professionals with USD or SGD wealth and family members in Singapore who want a fall-back domestic-rate insurer for treatment in Singapore (only Topaz Plus and above cover Singapore at the domestic rate)

Borderline Fit — Discuss but qualify carefully

• Customers comparing Sun Healthcare Solution directly to Allianz Flexi Medical, AlliSya Preferred Medical, or PRUWell — clearly disclose: Sun Healthcare Solution does not publish a No Claim Bonus or No Claim Discount, lacks an Initial Lifetime Limit booster like MediCare Protection, and its top tier (Safir Plus) caps at Rp 20B versus PRUWell Diamond’s Rp 72.5B combined
• Customers expecting USA treatment access at the top tier — Safir Plus pays only 30% of approved bill in the Worldwide-ex-Asia line, which the RIPLAY does not segregate USA from. Customers wanting full USA cover should look elsewhere
• Customers with significant pre-existing conditions — the SIO is fast but Sun Life can repudiate at claim time if the questionnaire missed a material condition. This is the structural downside of SIO. Walk through it explicitly
• Customers who view the Booster as guaranteed forever — the Booster steps until the Maximum Annual Ceiling is reached, then stops. After that, medical inflation is no longer offset by Booster; customer must consider plan upgrade
• Customers age 60–70 considering entry — premiums at attained age 60+ are materially higher than at age 40; the YRT structure means premium-shock risk in old age. Walk the Ilustrasi for ages 65 and 70 at issue
• Customers who say “I want the death benefit too” but only buy non-Plus tiers — Opal, Topaz, Emerald, Safir (non-Plus) have NO death benefit, no Booster. Buying non-Plus to save premium loses both differentiators

Do Not Pitch

• Customers wanting a CI lump-sum payout — Sun Healthcare Solution pays bills, not CI cash; if customer wants CI cash, recommend a CI rider on a base policy
• Customers wanting a long-term legacy / inheritance vehicle — the Rp 50M–Rp 200M death benefit is a small kicker, not a legacy
• Customers explicitly seeking maximum private-cancer cover at Singapore protocols — the Safir Plus Rp 20B max is structurally inadequate for full Singapore private oncology pathways; consider Indonesia-issued international health
• Customers expecting comprehensive USA treatment — no Sun Healthcare Solution tier covers USA at the domestic-equivalent rate
• Customers seeking guaranteed-issue with no health questions — SIO still has a health questionnaire and exclusions; not the same as guaranteed-issue
• Late-life prospects (70+) — entry age cap is 70 for Tertanggung and premium curve is steep
• Customers who have signaled likely lapse (income volatility, recent job loss, business stress) — YRT premium escalation and lapse-on-non-payment-after-60-days makes the product unforgiving

---

Rule of thumb: trigger words that move Sun Healthcare Solution into the conversation — “asuransi kesehatan tanpa cek medis,” “cashless Sun Life,” “limit otomatis naik,” “rawat di Singapura juga,” “tambahan santunan meninggal.” Trigger words that pull it out — “saya mau warisan” (the Rp 200M death benefit is not a legacy), “saya mau lump sum kalau kena penyakit kritis” (this is medical, not CI cash), “berobat ke Amerika” (top tier covers USA only at 30%), “saya mau nilai tunai” (no surrender value).

---

Drawn from the 2026-05-16 category-benchmarks.json: 33 catalogued health products in the Indonesia Life Insurance market intelligence inventory; 15 with sufficient analyzed data; coverage 45.5% — below the 60% quantitative threshold. Section 5 therefore relies on qualitative comparison from direct brief reading rather than formal worst/average/best benchmarking.

On STRUCTURAL design dimensions Sun Healthcare Solution sits in the top quartile of the catalogued health category: 8 plan tiers with a clear Base / Plus split, an auto-Booster mechanism on every Plus tier, a built-in death benefit on Plus tiers (rare in the hospitalization category), SIO underwriting, Indonesia + Malaysia + Singapore in the domestic Plus zone (Safir tier), and a coverage horizon to age 100. The Base / Plus structure is itself a distinctive marketing device — agents can up-sell Base to Plus by selling the Booster + Death Benefit pair.

On ECONOMIC dimensions Sun Healthcare Solution is mid-pack. The Safir Plus Rp 10B initial / Rp 20B maximum ceiling is competitive but not best in class — PRUWell Diamond combined Rp 72.5B is the category top. The Sun Medical Saver fixed-amount deductible is structurally distinctive in the catalogued set — most peers use percentage coinsurance, not a fixed rupiah-amount per-event. The premium-discount differential from electing Sun Medical Saver is meaningful (~25% in the specimen Topaz Plus case). The absence of any published No Claim Discount or No Claim Bonus mechanism is the visible economic gap versus PRUWell, MediCare Protection, and Manulife conventional health peers.

On COMPLIANCE / CONDUCT dimensions the product is moderately well-disclosed. The RIPLAY publishes the full 8-tier benefit table cleanly, two sample cases (with and without Sun Medical Saver), the 30-day general waiting period, the 12-month Penyakit Khusus list explicitly, and the 18-item Pengecualian set verbatim. The Sun Medical Saver math is shown in three claim-illustration tables including a Coordination of Benefit example. What is NOT yet visible in this v1/01/2025 RIPLAY edition: a POJK 36/2025 co-payment schedule (critical — see Section 8), the cashless-network hospital list, and the full premium-by-age table for all 8 plans.

Closest peer set for affluent-tier conventional hospitalization comparisons: PRUWell (Prudential), GEN MediCare Protection (Generali flagship), Allianz Flexi Medical (Allianz conventional), Manulife MiUltimate Healthcare. The structural moat is the Booster + Death Benefit + SIO bundle inside a single product — the rest of the structure is broadly matched by the peer set, and PRUWell beats Sun on raw ceiling, PRUWell/MediCare beat Sun on No Claim mechanics.

Confidence note: structural dimensions are high-confidence (benefit table is explicit and fully published). Economic dimensions are medium-confidence — only two specimen premium cases at age 40 male Topaz Plus are published; the full premium-by-age table is not in the RIPLAY-Umum. Compliance/conduct dimensions are medium-confidence — POJK 36/2025 implementation specifics are not yet visible in the v1/01/2025 RIPLAY edition. Refresh trigger: when Sun Life publishes a revised RIPLAY with POJK 36/2025 co-payment language, when premium-by-age table is published or extracted, when health category quantitative metric coverage exceeds 60%, or when Sun Life updates the plan tier structure or annual ceilings.

---

Opening — establish the honest competitive frame

“Sun Life Indonesia has been operating here for years. Their flagship medical product is Sun Healthcare Solution — eight plan tiers, auto-increasing annual ceiling on the Plus tiers, a small death benefit bundled in. Some of my customers compare Sun against what we offer. The honest answer is they’re different products with different design choices, and the right one depends on what you’re trying to do. Let me show you what Sun Healthcare Solution actually does, and where it does or doesn’t beat what we have.”

“Sun Life Indonesia sudah operasi di sini bertahun-tahun. Produk medical andalannya adalah Sun Healthcare Solution — delapan plan tier, limit tahunan otomatis naik di tier Plus, ada santunan meninggal kecil yang di-bundle. Beberapa nasabah saya bandingin Sun sama yang kita tawarin. Jawaban jujurnya, mereka produk berbeda dengan pilihan desain yang berbeda, dan mana yang tepat tergantung apa yang kamu mau capai. Saya tunjukin ya, apa yang Sun Healthcare Solution sebenarnya lakuin, dan di mana dia kalah atau menang dari yang kita punya.”

The structural value prop — the three Sun differentiators

“Three things make Sun Healthcare Solution distinctive. First — the Plus tiers have an auto-Booster. Every policy year, the annual ceiling steps up automatically. Topaz Plus starts at Rp 3 billion, adds Rp 150 million every year, capped at Rp 6 billion. Customer does nothing. The Booster is meant to offset medical inflation. Second — every Plus tier includes a small built-in death benefit, Rp 50 million on Opal Plus up to Rp 200 million on Safir Plus, paid if the insured dies before age 65. This is uncommon in hospitalization products. Third — no medical check at issuance. Just a health questionnaire. Fast onboarding. We’ll talk about the trade-off on that one because there is a real one. Those three together are Sun’s competitive answer.”

“Tiga hal yang bikin Sun Healthcare Solution beda. Pertama — tier Plus punya auto-Booster. Setiap tahun polis, limit tahunannya otomatis naik. Topaz Plus mulai Rp 3 miliar, nambah Rp 150 juta setiap tahun, mentok di Rp 6 miliar. Nasabah nggak ngapa-ngapain. Booster ini buat offset inflasi medis. Kedua — setiap tier Plus ada santunan meninggal kecil yang udah include, Rp 50 juta di Opal Plus sampai Rp 200 juta di Safir Plus, dibayar kalau tertanggung meninggal sebelum umur 65. Ini jarang ada di produk rawat inap. Ketiga — nggak ada cek medis pas issuance. Cuma kuesioner kesehatan. Onboarding cepat. Kita bakal bahas trade-off-nya karena memang ada. Tiga itu jawaban kompetitif dari Sun.”

The Booster pitch — and what it does NOT do

“The Booster is the most distinctive piece, so let’s be precise about what it does and doesn’t do. What it does: every policy year on a Plus tier, the annual ceiling steps up by a fixed amount — Rp 25 million on Opal Plus, Rp 150 million on Topaz Plus, Rp 225 million on Emerald Plus, Rp 500 million on Safir Plus. No claim-free condition. No separate rider needed. The customer does nothing. What it does NOT do: it does not step forever. There’s a Maximum Annual Ceiling — Rp 1 billion on Opal Plus, Rp 6 billion on Topaz Plus, Rp 9 billion on Emerald Plus, Rp 20 billion on Safir Plus. Once you hit the cap, the Booster stops. Medical inflation continues. From that point on, your real ceiling shrinks every year in inflation-adjusted terms unless you upgrade plans. So the Booster is a 10-to-25-year inflation buffer, not a permanent one. Plan for the day after the cap.”

“Booster adalah bagian yang paling beda, jadi mari kita teliti soal apa yang dilakuin dan apa yang nggak. Yang dilakuin: setiap tahun polis di tier Plus, limit tahunan naik dengan jumlah tetap — Rp 25 juta di Opal Plus, Rp 150 juta di Topaz Plus, Rp 225 juta di Emerald Plus, Rp 500 juta di Safir Plus. Nggak ada syarat klaim-free. Nggak perlu rider terpisah. Nasabah nggak ngapa-ngapain. Yang TIDAK dilakuin: dia nggak naik selamanya. Ada Batas Tahunan Maksimal — Rp 1 miliar di Opal Plus, Rp 6 miliar di Topaz Plus, Rp 9 miliar di Emerald Plus, Rp 20 miliar di Safir Plus. Begitu nyentuh batas, Booster berhenti. Inflasi medis lanjut. Sejak titik itu, limit sebenarnya kamu menyusut tiap tahun dalam nilai riil kecuali upgrade plan. Jadi Booster itu buffer inflasi 10-sampai-25-tahun, bukan permanen. Rencanakan hari setelah batas tercapai.”

The death-benefit kicker pitch — small, but real

“The Plus tier death benefit is small — Rp 50 to Rp 200 million depending on tier. It is not legacy planning. It is not a CI lump sum. What it is: a small immediate-cash kicker for funeral expenses and the first month of family logistics if the worst happens. The catch — it only pays if death happens before age 65. After age 65, the death benefit goes away; only the medical cover continues. For a Topaz Plus customer at age 40, that’s 25 years of small-death-benefit cover bundled into a medical premium they were going to pay anyway. Useful, but don’t oversell it as a life policy. If real life insurance is needed, that’s a separate conversation.”

“Santunan meninggal di tier Plus kecil — Rp 50 sampai Rp 200 juta tergantung tier. Ini bukan perencanaan warisan. Ini bukan lump sum penyakit kritis. Yang dia adalah: tambahan tunai kecil untuk biaya pemakaman dan satu bulan pertama logistik keluarga kalau hal terburuk terjadi. Catatan — dia cuma bayar kalau meninggal sebelum umur 65. Setelah 65, santunan meninggal hilang; cuma cover medis yang lanjut. Buat nasabah Topaz Plus umur 40, itu 25 tahun cover santunan meninggal kecil yang di-bundle ke premi medis yang memang dia bakal bayar. Berguna, tapi jangan over-sell sebagai polis jiwa. Kalau emang butuh asuransi jiwa nyata, itu obrolan terpisah.”

The close — honest comparison and lapse discipline

“Three final things. First — this is Yearly Renewable Term medical. There is no surrender value. If you lapse, all premiums paid are gone. The product is consumption, not savings. Second — your premium rises every year with your age. The number you see at age 40 is the starting point, not the average. At age 50, 60, 65 it’s materially higher every year. Before SPAJ I’ll run the Ilustrasi system and show you year-1, year-5, year-10, year-20 numbers. Third — be clear with me about what you’re insuring. If you want maximum private-hospital protection at the affluent tier and you can afford it, Safir Plus is the answer and we should also be comparing PRUWell Diamond. If you want a death benefit too, the Plus tiers include one — but don’t confuse this with real life insurance. There’s no wrong choice, just a wrong fit.”

“Tiga hal terakhir. Pertama — ini medical Yearly Renewable Term. Nggak ada nilai tunai. Kalau lapse, semua premi yang udah dibayar hilang. Produknya konsumsi, bukan tabungan. Kedua — premi kamu naik setiap tahun ngikutin umur. Angka yang kamu lihat di umur 40 itu titik awal, bukan rata-rata. Di umur 50, 60, 65 jauh lebih tinggi setiap tahun. Sebelum SPAJ saya buka sistem Ilustrasi dan tunjukin angka tahun-1, tahun-5, tahun-10, tahun-20. Ketiga — jujur sama saya apa yang kamu asuransikan. Kalau kamu mau proteksi rumah sakit swasta maksimal di tier affluent dan sanggup, Safir Plus jawabannya dan kita harus juga bandingin PRUWell Diamond. Kalau kamu mau santunan meninggal juga, tier Plus include itu — tapi jangan rancuin sama asuransi jiwa beneran. Nggak ada pilihan yang salah, yang ada cuma cocok atau nggak.”

—

1. “Premi naik setiap tahun ngikutin umur. Di umur 50 gimana? Umur 65?”

“Premium rises every year with age. What does it look like at 50? At 65?”

Don't say “Naiknya nggak banyak kok.” — false; medical inflation in Indonesia runs 20–26% a year.

Don't say “Naiknya nggak banyak.”

Do say “I won’t pretend otherwise. Medical inflation in Indonesia runs 20–26% per year, and Yearly Renewable Term medical products are age-loaded on top. At age 40 male on Topaz Plus, the specimen RIPLAY case is Rp 11.862 million per year without Sun Medical Saver, or about Rp 8.897 million per year with Sun Medical Saver elected. At age 50 it will be meaningfully higher. At age 60 — closing on the 70-year entry-age cap — higher again. Before you sign, I will open the Ilustrasi system and show you the year-1, year-5, year-10, year-15, year-20 numbers for your specific age and plan. Numbers you see, not numbers I tell you. And remember the RIPLAY clause that says Sun reserves the right to revise premium beyond age curve with 30-working-day notice based on claim experience — that’s an honest disclosure I need to walk through with you.”

Do say “Saya nggak akan pura-pura. Inflasi medis Indonesia 20–26% per tahun, dan produk medical Yearly Renewable Term itu age-loaded di atasnya. Di umur 40 cowok Topaz Plus, ilustrasi RIPLAY-nya Rp 11,862 juta per tahun tanpa Sun Medical Saver, atau sekitar Rp 8,897 juta per tahun dengan Sun Medical Saver. Di umur 50 jauh lebih tinggi. Di umur 60 — mendekati batas usia masuk 70 — lebih tinggi lagi. Sebelum tanda tangan, saya buka sistem Ilustrasi dan tunjukin angka tahun-1, tahun-5, tahun-10, tahun-15, tahun-20 buat umur dan plan kamu spesifik. Angka yang kamu lihat, bukan yang saya bilangin. Dan ingat klausul RIPLAY yang bilang Sun berhak ubah premi di luar kurva umur dengan pemberitahuan 30 hari kerja berdasarkan pengalaman klaim — itu disclosure jujur yang harus saya jalanin sama kamu.”

—

2. “Limit Sun Healthcare Solution naik otomatis tiap tahun. Kenapa nggak ini aja yang paling baik?”

“Sun Healthcare Solution’s ceiling auto-rises every year. Isn’t this just the best?”

Don't say “Itu cuma marketing.” — dismissive and false; the Booster is a real mechanism.

Don't say “Itu cuma marketing.”

Do say “The Booster is real and it’s a genuine value feature. But it isn’t permanent. Let me walk you through what happens. Topaz Plus starts at Rp 3 billion. Adds Rp 150 million every policy year. Hits Rp 6 billion at year 21. After that, the Booster stops. From year 22 onwards your ceiling is fixed at Rp 6 billion while medical inflation continues at 20–26% per year. In real terms, year 22’s Rp 6 billion is worth a fraction of year 1’s Rp 3 billion. So the Booster is a 21-year inflation buffer on Topaz Plus, not a permanent escalator. Compare that to a product with a No Claim Bonus that tops up the cover indefinitely based on claim-free years — that’s a different mechanic that may suit you better depending on your expected claim pattern. Honest answer: the Booster is good for the first 20 years; after that, the customer needs to either upgrade plans or hold a different product. Plan for both phases at SPAJ.”

Do say “Booster-nya nyata dan itu fitur nilai yang asli. Tapi dia nggak permanen. Saya jalanin kamu. Topaz Plus mulai Rp 3 miliar. Nambah Rp 150 juta setiap tahun polis. Nyentuh Rp 6 miliar di tahun 21. Setelah itu Booster berhenti. Dari tahun 22 ke depan limit kamu fixed di Rp 6 miliar sedangkan inflasi medis terus 20–26% per tahun. Dalam nilai riil, Rp 6 miliar di tahun 22 itu sekuel dari fraksi Rp 3 miliar di tahun 1. Jadi Booster itu buffer inflasi 21-tahun di Topaz Plus, bukan eskalator permanen. Bandingin sama produk dengan No Claim Bonus yang nambah cover terus berdasarkan tahun-tahun klaim-free — itu mekanik berbeda yang bisa lebih cocok buat kamu tergantung pola klaim yang kamu ekspektasi. Jawaban jujurnya: Booster bagus buat 20 tahun pertama; setelah itu, nasabah harus upgrade plan atau pegang produk berbeda. Rencanain dua fase pas SPAJ.”

—

3. “Sun nggak perlu cek medis. Itu kan enak banget?”

“Sun doesn’t require a medical check. That sounds great, right?”

Don't say “Iya, gampang banget masuknya.” — encourages the customer to under-disclose.

Don't say “Iya, gampang banget masuknya.”

Do say “Easy to enter, yes. But there’s a real trade-off you need to understand. Simplified Issuance Offer means underwriting is light at the front — but it’s heavy at claim time. If at first claim Sun’s underwriter discovers you had a material health condition before issuance that you didn’t fully disclose on the questionnaire, the claim can be denied and the policy retroactively cancelled. With a full medical check at issuance, that risk is mostly priced in upfront. With SIO, it’s deferred until you actually claim. So the real cost of ‘no medical check’ is paid later, by the families that find out their claim isn’t covered for a condition that existed but wasn’t fully captured on the questionnaire. The fix: be exhaustive on the health questionnaire. Disclose every consultation, every test result, every medication, every family-history flag. If your agent rushes you through it, slow them down. The questionnaire is the most important document you’ll sign on this product.”

Do say “Iya gampang masuknya. Tapi ada trade-off nyata yang kamu harus paham. Simplified Issuance Offer artinya underwriting-nya ringan di depan — tapi berat pas klaim. Kalau di klaim pertama underwriter Sun nemu kamu punya kondisi kesehatan material sebelum issuance yang nggak kamu disclose penuh di kuesioner, klaim bisa ditolak dan polis dibatalkan retroaktif. Dengan cek medis lengkap di issuance, risiko itu sebagian besar udah di-price-in di depan. Dengan SIO, ditunda sampai kamu beneran klaim. Jadi cost sebenarnya dari ‘nggak ada cek medis’ itu dibayar belakangan, sama keluarga yang baru tahu klaimnya nggak ditanggung buat kondisi yang ada tapi nggak ke-capture penuh di kuesioner. Solusinya: eksaustif di kuesioner kesehatan. Disclose setiap konsultasi, setiap hasil tes, setiap obat, setiap riwayat keluarga. Kalau agen kamu buru-buru, suruh dia lambatin. Kuesioner itu dokumen paling penting yang bakal kamu tanda tangani di produk ini.”

—

4. “Limit Safir Plus Rp 10 miliar. Kalau saya kena kanker di Singapura, cukup nggak?”

“Safir Plus ceiling is Rp 10 billion. If I get cancer in Singapore, is that enough?”

Don't say “Pasti cukup kok.” — overpromising; depends on the protocol.

Don't say “Pasti cukup.”

Do say “Fair question, and the honest answer depends on the protocol. Standard Singapore private cancer pathways — early-stage, surgical, and one line of chemotherapy or targeted therapy — typically run S$200K to S$500K, which is roughly Rp 2.4 to Rp 6 billion. Safir Plus initial ceiling Rp 10 billion handles that. Multi-line advanced cancer — immunotherapy, CAR-T, multi-year regimens, transplant pathways — can run S$800K to S$1.5M, which is Rp 9.6 to Rp 18 billion. Safir Plus initial ceiling is just at the edge; after Booster steps to Rp 20 billion max over 20 years, the ceiling is comfortable. For customers genuinely concerned about catastrophic Singapore cancer protocols, the structural answer is either Safir Plus with full Booster runway, or a separate international health policy with a higher Singapore ceiling. PRUWell Diamond’s combined Rp 72.5B is also worth comparing if pure capacity is the goal. I won’t pretend Safir Plus alone is the best answer for the rare worst case. It’s a good answer for typical and moderately severe cases, with structural room to grow.”

Do say “Pertanyaan yang valid, dan jawaban jujurnya tergantung protokolnya. Jalur kanker swasta Singapura standar — stadium awal, bedah, satu lini kemoterapi atau terapi target — biasanya S$200K sampai S$500K, sekitar Rp 2,4 sampai Rp 6 miliar. Limit awal Safir Plus Rp 10 miliar handle itu. Kanker stadium lanjut multi-lini — imunoterapi, CAR-T, regimen multi-tahun, jalur transplantasi — bisa S$800K sampai S$1,5 juta, atau Rp 9,6 sampai Rp 18 miliar. Limit awal Safir Plus pas di tepi; setelah Booster naik ke maksimum Rp 20 miliar selama 20 tahun, limit-nya nyaman. Buat nasabah yang beneran khawatir protokol kanker katastropik di Singapura, jawaban strukturalnya antara Safir Plus dengan runway Booster penuh, atau polis kesehatan internasional terpisah dengan limit Singapura lebih tinggi. PRUWell Diamond combined Rp 72,5 miliar juga layak dibandingin kalau tujuan utamanya kapasitas murni. Saya nggak akan pura-pura Safir Plus sendirian itu jawaban terbaik buat worst case yang jarang. Dia jawaban baik buat kasus tipikal dan moderately severe, dengan ruang struktural buat tumbuh.”

—

5. “Sun ada Santunan Meninggal Rp 200 juta. Bisa nggak ini gantiin asuransi jiwa saya?”

“Sun has a Rp 200 million death benefit. Can this replace my life insurance?”

Don't say “Iya bisa.” — false and dangerous; this is a small kicker, not life cover.

Don't say “Iya bisa.”

Do say “Honest answer: no. The Plus-tier death benefit is small and limited. Two facts to know. First, it ranges from Rp 50 million on Opal Plus to Rp 200 million on Safir Plus. For most middle-income families with one or two dependents, that doesn’t cover even one year of household expenses. Real life insurance should be sized to 5 to 10 years of household income, which is typically Rp 1 to Rp 5 billion. Second, the death benefit only pays if death happens before age 65. After 65, the death benefit goes away — only the medical cover continues. So it’s a small immediate-cash kicker for the first 25 years on a Topaz Plus customer age 40, not a real legacy structure. If you genuinely want life protection for your family, we should talk about a separate term-life or whole-life policy sized to your actual income-replacement need. The Sun Plus death benefit is a bonus on top of the medical cover, not a substitute for life insurance.”

Do say “Jawaban jujur: nggak. Santunan meninggal tier Plus itu kecil dan terbatas. Dua fakta yang harus kamu tahu. Pertama, dia mulai dari Rp 50 juta di Opal Plus sampai Rp 200 juta di Safir Plus. Buat kebanyakan keluarga middle-income dengan satu atau dua tanggungan, itu nggak nutup bahkan satu tahun pengeluaran rumah tangga. Asuransi jiwa beneran harus di-size ke 5 sampai 10 tahun penghasilan rumah tangga, yang biasanya Rp 1 sampai Rp 5 miliar. Kedua, santunan meninggal cuma bayar kalau meninggal sebelum umur 65. Setelah 65, hilang — cuma cover medis yang lanjut. Jadi dia kicker tunai cepat yang kecil buat 25 tahun pertama buat nasabah Topaz Plus umur 40, bukan struktur warisan beneran. Kalau kamu beneran mau proteksi jiwa buat keluarga, kita harus ngobrol soal polis term-life atau whole-life terpisah yang di-size ke kebutuhan income-replacement kamu beneran. Santunan meninggal Sun Plus itu bonus di atas cover medis, bukan pengganti asuransi jiwa.”

—

These are the issues most likely to trigger an OJK complaint or a customer churn event under tightened 2026 conduct rules. Build agent training around avoiding each.

1. POJK 36/2025 co-payment regime — effective January 2026, currently NOT in the RIPLAY. The Sun Healthcare Solution RIPLAY reviewed (v1/01/2025) was issued ahead of the POJK 36/2025 effective date. It does NOT publish a regulatory co-payment schedule, even though POJK 36/2025 applies to health products from Jan 2026. The product’s existing Sun Medical Saver is an elective customer feature (a fixed-amount deductible), not a POJK-mandated participation. Agents — including Legacy Income agents discussing this competitor — must not represent Sun Medical Saver as “the POJK co-payment.” These are conceptually different. Agents must warn customers that Sun Life may publish a revised RIPLAY adding POJK 36/2025 customer-share schedules separate from Sun Medical Saver, and that Polis-level terms may evolve. Mis-quoting the current Sun Medical Saver structure as a permanent and exhaustive customer-share story is a material misrepresentation risk.

2. Yearly Renewable Term premium-escalation walk-through is non-negotiable. Premium changes every policy anniversary based on Tertanggung’s attained age. The brochure publishes Rp 5.931M at age 40 male Topaz Plus as the entry-year premium. By age 50 the premium is materially higher; by age 60 significantly higher; by age 70 (the entry cap) substantially higher again. Customers who sign without seeing the Ilustrasi system year-1-to-year-20 schedule will be shocked at renewal and likely complain. The agent must open the Ilustrasi for the customer’s specific age and plan and document customer’s verbal acknowledgment of the escalation curve. Additionally, the RIPLAY clause that Sun reserves the right to revise premium with 30-working-day notice based on claim experience must be spoken aloud at SPAJ — this is a real and material risk separate from the age curve.

3. Booster mechanism explanation — auto-step but capped. Customers easily hear “annual ceiling auto-increases” and assume that means permanent inflation protection. It does not. The Booster steps until the Maximum Annual Ceiling is reached, then stops. On Topaz Plus that’s Rp 3B → Rp 6B over 21 years; from year 22 onwards, the ceiling is fixed. Medical inflation continues thereafter. Agents who pitch “your ceiling always grows” without disclosing the cap are mis-selling. The full Booster trajectory and cap must be walked through using the brochure’s own Topaz Plus age-40 example, and customer must verbally confirm understanding.

4. Geographic coverage exclusions — and the no-USA cliff. The brochure publishes a 4-region payout schedule. For Opal/Topaz/Emerald and their Plus variants: Indonesia is domestic-rate, Malaysia 85%, Singapore 60%, Asia ex-Indonesia/Malaysia/Singapore 35%, Worldwide ex-Asia 20%. For Safir/Safir Plus: Indonesia + Malaysia + Singapore domestic-rate, Asia ex-Indo/MY/SG 55%, Worldwide ex-Asia 30%. There is no explicit USA-only line — USA falls into “Worldwide ex-Asia” at 20% (Topaz Plus etc) or 30% (Safir Plus). Customers expecting US treatment access at the top tier will be disappointed: the headline cap of Rp 20B Safir Plus only goes 30% of approved bill in the Worldwide-ex-Asia line, and US private oncology, cardiac, or transplant pathways routinely exceed the cap even at 30%. Agents must walk the customer through the geographic schedule verbatim and disclose explicitly that USA is not a domestic-rate territory.

5. Pre-existing condition disclosure and the Penyakit Khusus 12-month list. The RIPLAY excludes pre-existing conditions (Kondisi Yang Telah Ada Sebelumnya) unless explicitly accepted in writing by Sun Life. Separately, the 12-month Penyakit Khusus list covers hernia (incl. HNP), endometriosis/fibroid/myoma and reproductive-system conditions, all cysts/tumors benign or malignant, TB, asthma and COPD, anal fistula/perianal abscess/haemorrhoid, diabetes/cholecystitis/gallstones/all hepatitis except A/cirrhosis, tonsils and adenoids requiring surgery, urinary tract conditions and kidney disease, nasal/sinus/septum abnormalities, thyroid/parathyroid disorders, gastritis/ulcer/perforation, cataract, hallux valgus, all epilepsy, all spine/disc conditions, hypertension/cardiac/cerebrovascular incl. TIA/stroke/migraine/vertigo, blood disorders (anaemia, lupus, leukaemia), and all knee conditions. Customers must not be told they can claim a stroke, cardiac event, or cancer in month 6 — these all fall in the 12-month Penyakit Khusus list. Agents conflating “30-day waiting” with the 12-month specific-conditions list are mis-selling.

6. Simplified Issuance Offer (SIO) — the front-loaded upside, the back-loaded downside. SIO has both an upside (easy onboarding, no medical check, fast issuance) and a structural downside (claim-time review for non-disclosure). Agents must walk customers through this carefully. Best-practice script: “If at first claim Sun discovers a material health condition you had before issuance and didn’t fully disclose on the questionnaire, the claim can be denied and the policy retroactively cancelled. So the underwriting cost is deferred to claim time. The fix: be exhaustive on the questionnaire. Disclose every prior consultation, every test result, every medication, every family-history flag. Don’t let me or anyone rush you through the questionnaire.” Document the customer’s verbal acknowledgment. The SIO claim-repudiation pattern is the single most common Sun Life complaint vector in OJK conduct data.

7. Sun Medical Saver math walk-through — fixed-amount deductible, not percentage coinsurance. Sun Medical Saver is structurally different from peer products’ percentage coinsurance (e.g., AlliSya 80/20, GLH Lite Saver 80/20). It is a fixed-rupiah amount per hospitalization event that the customer absorbs before Sun pays — Rp 8M (Opal Plus) to Rp 20M (Safir Plus). The premium discount is ~25% in the Topaz Plus specimen case. Agents must use the RIPLAY’s own three sample tables (single claim, COB with another insurer, Santunan Tunai Harian Rawat Inap with COB) to walk customers through the math in cash terms. Customers who sign without understanding the per-event absorption will be surprised at the first claim. Document the customer’s verbal acknowledgment of the fixed-amount deductible mechanic.

8. Death benefit on Plus tier — small kicker, not life insurance. The Plus-tier death benefit (Rp 50M Opal Plus to Rp 200M Safir Plus) pays only if death occurs before age 65. After age 65, the death benefit disappears; only the medical cover continues. Customers who think they’re buying meaningful life cover via the medical policy will be misled. Agents must clearly disclose: this is a small immediate-cash kicker for the first 25 years on a typical Topaz Plus customer age 40, not a substitute for a real life insurance policy. The customer’s actual life-insurance need must be assessed separately. Selling the Sun Healthcare Solution Plus tier as a “two-in-one” without surfacing this distinction is mis-selling.

---

---

1. Build a “Sun Healthcare Solution vs Allianz Flexi Medical” side-by-side comparison sheet. Bilingual EN+ID, single page. Left column Sun Healthcare Solution Topaz Plus and Safir Plus, right column Allianz Flexi Medical Diamond and Platinum (or equivalent tiers). Rows: insurer, channel, base requirement, tier count, annual ceiling structure, Booster mechanism (auto-Booster vs Annual Limit Booster), No Claim Discount/Bonus, geographic ladder (especially Singapore and Malaysia treatment %), USA cover, death benefit bundling (Sun has it, Allianz does not), Risiko Sendiri / Sun Medical Saver / Allianz coinsurance equivalent, premium specimen at age 40 male and age 50 male, SIO vs full underwriting. Deliverable target: an agent uses this sheet whenever a prospect mentions Sun Life, so the conversation moves to structural fit rather than price-only or brand-only.

2. Train agents on the Booster argument and what beats it. Drill agents on the auto-Booster mechanism, the per-tier cap, and the year-by-year escalation maths so they can speak fluently when a customer says “Sun has auto-Booster.” Pair-train on three counter-arguments Legacy Income agents can deploy: (a) Booster steps until the cap then stops — beyond year 21 on Topaz Plus, Allianz Flexi Medical or AlliSya Preferred Medical with No Claim Bonus or Annual Limit Booster mechanics may give better long-tail inflation protection; (b) the Booster only operates on Plus tiers, which carry materially higher premium than equivalent base tiers; © compare against Allianz Annual Limit Booster mechanic side by side using actual sample bills. Bilingual collateral, drill-tested at agency training.

3. Build the YRT premium-escalation customer education collateral. Bilingual EN+ID handout. Front: the brochure’s own Rp 5.931M/yr Topaz Plus age-40 specimen with an explicit year-1 through year-30 projection at a 12% YRT escalation curve (typical Indonesian medical YRT), showing the rupiah burden at age 50, 60, 70. Back: “what to ask your agent before you sign Sun Healthcare Solution” checklist — Ilustrasi numbers for year 5, 10, 15, 20; the 30-working-day premium-revision clause; the Booster cap; the SIO repudiation risk; the geographic schedule. Deliverable target: Legacy Income agents hand this out when a prospect is comparing or has already been pitched Sun Healthcare Solution. Compliance-clean, fact-based, no anti-competitor language.

4. Sample-case battle-test against Sun Life Ilustrasi. In a controlled training environment, have an agent open both a Sun Healthcare Solution Ilustrasi (via a known Sun Life agent contact or publicly available illustrator if any) AND an equivalent Allianz Flexi Medical / AlliSya Preferred Medical Ilustrasi for the same prospect profile (age 40 male, age 45 female, age 55 male). Capture the year-1, year-5, year-10, year-15, year-20 premium and ceiling for each. Use this battle-test as the basis for the comparison sheet in action item 1 and the training in action item 2. This is the single highest-leverage one-time investment for handling Sun Healthcare Solution objections at the SPAJ table.

5. Lapse-and-surrender risk briefing for agents. Document and drill the structural point that Sun Healthcare Solution has no surrender value — it is consumption, not savings. Legacy Income agents should be ready to surface this when a prospect mentions Sun Healthcare Solution as a “savings + medical” product (a common but inaccurate consumer perception). Pair with Allianz Flexi Medical’s structural equivalents and document the lapse statistics: a customer who lapses a Topaz Plus at year 8 has paid roughly Rp 75M+ in premium for zero residual value. This isn’t anti-Sun; it’s anti-mis-buying. The same applies to Allianz medical products. Train agents to position the medical product as protection, not investment, and recommend a separate savings vehicle if the customer also wants a savings outcome.

---